Since our founding, we have developed an extensive and proprietary set of platform technologies to enable the discovery and development of novel therapies across a wide range of therapeutic targets. With an initial focus in oncology, we and our partners have leveraged our platforms and are currently advancing pipelines of novel bi- and multi-specific antibody candidates that have demonstrated unparalleled combinatorial specificity and best-in-class potential in pre-clinical studies to date. With our growing portfolio of innovations, we intend to expand our pipeline across additional disease categories, creatively optimizing candidates to address even the most challenging of therapeutic targets.
Headquartered in Madison, Wisconsin, we are a private company committed to our Core Values and advancing patient health.
“For decades, new treatments for advanced cancer were considered successful if they could slow the cancer’s growth and extend survival a few months. We should aim for more than a few months. Our goal must remain eliminating all cancer in patients and preventing cancer from ever coming back.“
— Paul Sondel, MD, PhD
Reed and Carolee Walker Professor
of Pediatric Oncology
Co-leader, Cancer Immunology
University of Wisconsin
Carbone Cancer Center